Technical data

Deaths in Gambia | India seeks more data

Data on the clinical characteristics and treatment received by the children so far are insufficient, India’s Comptroller General of Medicines VG Somani said in his letter to the World Health Organization.

Data on the clinical characteristics and treatment received by the children so far are insufficient, India’s Comptroller General of Medicines VG Somani said in his letter to the World Health Organization.

India has requested more information from the World Health Organization on deaths in The Gambia linked to contaminated cough syrups manufactured by Maiden Pharma in India.

The clinical characteristics and treatment received by the children as shared by the World Health Organization so far are insufficient to determine the etiology, India’s Comptroller General of Medicines VG Somani said in his letter on Friday. to the World Health Organization, while addressing the suspected case. of tainted cough medicine and cold syrup from India, manufactured by Maiden Pharmaceutical Limited, which is believed to have been the contributing factor in the deaths of more than 60 children in The Gambia.

He said the Ministry of Health had set up a committee of technical experts which had met. The team researched details of the original illness; Signs and symptoms; duration of anuria in cases; the results of the laboratory investigations carried out, including various markers and parameters; Specific investigations for ethylene glycol (EG) and diethylene glycol (DEG) on clinical samples of patients and treatments received before and after hospitalization at the tertiary hospital in The Gambia.

“The reasons for these, the names and brands of the drug formulations used in the treatment before and after hospitalization, their manufactures, their expiration and any other relevant information in each of the cases are necessary,” he said. stated in the letter.

He also noted that in the event of a verbal autopsy, a detailed report of it could be shared by the WHO.

Editorial | No time for a placebo: on the regulation of death and medicine in The Gambia

The ministry said it needed more information on the number of stool samples collected and tested, the number of children with a clinical presentation similar to acute renal failure from whom the biological samples were collected and details of the test method adopted to test the samples.

Dr. Somani added that India wants a report on casual relations and details of product samples collected and tested which were reported as negative for EG and DEG and details of cases who received these products are needed to analyze the events.